Invention Grant
- Patent Title: COMT inhibitors
-
Application No.: US14752177Application Date: 2015-06-26
-
Publication No.: US09656971B2Publication Date: 2017-05-23
- Inventor: Caterina Bissantz , René Bonnafous , Bernd Buettelmann , Roland Jakob-Roetne , Christian Lerner , Markus Rudolph
- Applicant: Hoffmann-La Roche Inc.
- Applicant Address: US NJ Little Falls
- Assignee: Hoffmann-La Roche Inc.
- Current Assignee: Hoffmann-La Roche Inc.
- Current Assignee Address: US NJ Little Falls
- Agency: Genentech, Inc.
- Agent Mark D. Kafka
- Priority: EP12199491 20121227
- Main IPC: C07D239/88
- IPC: C07D239/88 ; C07D471/04 ; C07D417/10 ; C07D417/04 ; C07D413/04 ; C07D409/04 ; C07D409/06 ; C07D409/14 ; C07D405/04 ; C07D403/04 ; C07D401/04 ; C07D401/10 ; C07D401/12 ; C07D403/10 ; C07D401/06
Abstract:
The present invention relates to compounds of formula wherein the substituents are described in claim 1 and to the pharmaceutically acceptable salts thereof. These compounds inhibit the enzyme catechol-O-methyltransferase (COMT). The compounds may be used for the treatment of Parkinson's disease, depression, cognitive impairment and motor symptoms, resistant depression, cognitive impairment, mood and negative symptoms of schizophrenia.
Public/Granted literature
- US20160002177A1 COMT INHIBITORS Public/Granted day:2016-01-07
Information query
